Stemson Therapeutics Secures $7.5 Million Financing for Development of Hair Regeneration Therapy

September 16, 2020

Stemson Therapeutics has announced a $7.5-million seed financing led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital to advance development of Stemson’s therapeutic solution to cure hair loss. Stemson aims to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles. Allergan Aesthetics is a world-leading medical aesthetics company. Fortunis Capital, a London-based venture capital firm, is committed to continuing support of Stemson’s regenerative cell therapy to treat hair loss. Fortunis Capital’s new Impact Fund intends to invest in companies, such as Stemson, that offer significant social or environmental benefit.
Read more at Business Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • PracticeQ Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Fresh Clinics Acquires Spakinect
    • Arkansas Nursing Board Comment Deadline Approaching for Medical Aesthetics and IV Hydration Guidance
    • Acquisition Lets AI and Operators Learn From Nearly $2 Billion in Annual Aesthetics Transactions
    • Galderma Celebrates 30 Years of Restylane